August 03, 2017 02:04 PM Eastern Daylight Time
SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today the appointment of William J. Polvino, M.D. to its business advisory board.
SAB, founded in 2014, develops human antibody therapeutics using its first-of-its-kind immunotherapy platform. The company’s first two immunotherapies are in clinical trials, with other infectious disease, oncology and autoimmune targets in development.
Dr. Polvino is a pharmaceutical entrepreneur with more than 26 years of experience in the healthcare arena. He is currently the CEO of Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic.
“SAB has been working with Dr. Polvino through various industry connections. He has been a champion in advancing our immunotherapy platform,” said Eddie Sullivan, Ph.D., president and CEO of SAB Biotherapeutics. “We are thrilled to have him join us in a more formal capacity as we forge a path with our powerful polyclonal platform.”
Prior to Bridge Medicines, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals A/S (NASDAQ: VELO), a public biotechnology company that deployed proprietary formulation technology to develop and commercialize an innovative oral drug product for transplant patients. Polvino also served as president CEO of Helsinn Therapeutics (formerly Sapphire Therapeutics), and has held executive and senior-level positions in drug development at Merck, Wyeth and Theravance.
“As a medical doctor, he brings a lot of passion to what we’re doing in terms of immunology and it’s potential impact on patients,” added Sullivan. “As a pharma entrepreneur, Dr. Polvino understands the potential of our unique science and what we need to do to further build the company to get life-saving therapies to the clinic.”
Dr. Polvino trained in internal medicine at Massachusetts General Hospital and was a fellow in clinical pharmacology at the National Institutes of Health prior to entering the pharmaceutical and biotechnology industry.
“It is a privilege to be joining the Business Advisory Board for SAB Biotherapeutics,” said William J. Polvino, M.D. “The Company’s founding technology provides a new platform for human antibody production with breakthrough potential for addressing unmet medical needs.”
SAB is developing products for several targets including seasonal influenza, mycoplasma, C-Diff, Zika and Ebola. In addition, a Phase I Clinical Trial with the National Institutes of Health for its treatment for MERS-CoV is nearly complete and has funding support from BARDA for Phase 2.
“The technology has demonstrated exciting, early preclinical and clinical results across an array of disease states and is now poised for significant advancement as a pioneering antibody discovery platform,” added Polvino. “The team of talented professionals at SAB has demonstrated the ability to deliver meaningful results through advancement of cutting edge science.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science in the world, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
Contacts
SAB Biotherapeutics, Inc.
Melissa Ullerich, +1-605-695-8350
media@sab.bio
